ERBB2 and breast carcinoma: Moreover, many studies revealed that SHC1 participated in signalling through epidermal growth factor receptor‐2 (HER‐2), oestrogen receptor (ER) and prolactin (PR) signalling, which were well‐recognized biological markers for predicting prognosis and response to breast cancer therapy.57, 58, 59